Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intraperitoneal immunoconjugates.

T W Griffin1, J Collins, F Bokhari

  • 1Division of Oncology (Medicine), University of Massachusetts Medical School, Worcester 01655.

Cancer Research
|February 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Obesity Paradox in the Trauma Patient: Normal May not Be Better.

World journal of surgery·2020
Same author

Studies of aluminum in rat brain.

Biological trace element research·2013
Same author

A randomized trial investigating an iron-rich bread as a prophylaxis against iron deficiency in pregnancy.

International journal of food sciences and nutrition·2011
Same author

Can an iron-rich staple food help women to achieve dietary targets in pregnancy?

International journal of food sciences and nutrition·2011
Same author

A study to establish whether food-based approaches can improve serum iron levels in child-bearing aged women.

Journal of human nutrition and dietetics : the official journal of the British Dietetic Association·2011
Same author

Physics applications in nuclear medicine: 2008 in review.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2009
Same journal

CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer.

Cancer research·2026
Same journal

A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies.

Cancer research·2026
Same journal

Editor's Note: Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib.

Cancer research·2026
Same journal

Editor's Note: Deguelin Analogue SH-1242 Inhibits Hsp90 Activity and Exerts Potent Anticancer Efficacy with Limited Neurotoxicity.

Cancer research·2026
Same journal

Retraction: Two Functional Epitopes of Pigment Epithelial-Derived Factor Block Angiogenesis and Induce Differentiation in Prostate Cancer.

Cancer research·2026
Same journal

Editor's Note: Chronic Stress Facilitates Lung Tumorigenesis by Promoting Exocytosis of IGF2 in Lung Epithelial Cells.

Cancer research·2026
See all related articles

Intraperitoneal (IP) radioantibody therapy shows promise for localized cancers. This approach reduces isotope uptake in organs like the liver and kidneys, offering a potential advantage over intravenous administration for confined malignant disease.

Area of Science:

  • Oncology
  • Immunotherapy
  • Radiopharmaceutical Therapy

Background:

  • Intracavitary instillation of radioantibodies is a potential therapy for anatomically confined malignant disease.
  • The human transferrin receptor is a target for monoclonal antibody therapy.

Purpose of the Study:

  • To evaluate the localization of a monoclonal antibody (7D3) targeting the human transferrin receptor for intracavitary radioantibody therapy.
  • To compare the biodistribution of radioantibodies administered via intraperitoneal (IP) versus intravenous (IV) routes in a preclinical model.

Main Methods:

  • A monoclonal antibody (7D3) reactive with the human transferrin receptor was purified and radiolabeled with 131I, 125I, or 111In.
  • Radiolabeled antibody was administered IP or IV to athymic nude mice bearing human malignant mesothelioma xenografts.

Related Experiment Videos

  • Biodistribution was assessed by measuring the percentage of injected dose per gram (% ID/g) in tumors and organs at various time points.
  • Clinical studies in ovarian cancer patients receiving IP radioantibodies were also reviewed.

    • Main Results:

    • IP administration resulted in higher initial tumor cell uptake of radiolabel compared to IV administration in free-floating ascites cells (31.0% ID/g vs 12.0% ID/g at 3h).
    • Localization in solid tumors was similar between IP and IV routes at 3h (5.37% ID/g vs 4.73% ID/g).
    • By 24h, both routes showed similar tumor localization.
    • IP administration led to significantly less radiolabel uptake in the liver, kidney, bone, and bone marrow compared to IV administration.
    • Clinical studies showed confined biodistribution with IP radioantibodies, though with interpatient variability in radiolabel egress.

    Conclusions:

    • IP radioantibody therapy may be advantageous for cancers confined to the peritoneal cavity due to reduced systemic exposure to the isotope.
    • The primary benefit appears to be reduced localization in organs of toxicity (liver, kidney, bone, bone marrow), not necessarily higher tumor levels.
    • Further research is needed to address antibody penetration into solid tumors, microdosimetry, and the overall effectiveness of radioantibody therapy for tumor killing.